Clinical trials: Genome Instability
Colorectal Cancer, Colorectal Cancer Metastatic
Dynamics of MSI and Genomic Profile of Colorectal Cancer In the Course of Immune Checkpoint Inhibitor Therapy
Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. Microsatellite instability or mismatch repair deficiency occurs in 20% of CRC, and is predominantly found in non-metastatic tumors.
- Conditions
- Colorectal Cancer, Colorectal Cancer Metastatic, MSI-H Colorectal Cancer, dMMR Colorectal Cancer
- Trial name
- BLOOMSI (NCT06414304)
- Where
- 2 sites in Russia
- Volunteers
- 30 people
- Sponsor
- OncoAtlas LLC
Endometrial Neoplasms, TP53 Gene Mutation
Translational Study of MSS, TP53 Mutation and Chromosome Instability Relationship in Endometrial Carcinoma
The objective is to understand the relationship between TP53 mutation, MSS and chromosome instability in endometrial cancer and the effect on clinical prognosis.We will collect a small amount of tumor tissue samples.
- Conditions
- Endometrial Neoplasms, TP53 Gene Mutation, Chromosomal Instability, Microsatellite Stable Endometrial Carcinoma
- Trial name
- NCT06521684
- Volunteers
- 110 people
- Sponsor
- Peking Union Medical College Hospital
Anesthesia; Adverse Effect
Does Sevoflurane Cause Genomic Damage
This study aims to find out if sevoflurane causes any cell damage to patients undergoing general anaesthesia. In case of any damage, the reversibility of the damage is also assessed.
- Trial name
- NCT03109119
- Testing
- Sevoflurane, Propofol
- Where
- India
- Volunteers
- 30 people
- Sponsor
- Jubilee Mission Medical College and Research Institute
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Colorectal Cancer
Association of MSI, TS, DPD, MVD and EGFR With Chemosensitivity in Stage IV in Colorectal Cancer
The present project will follow our previous phaseⅡ study of FOLFOX regimens for the treatment of stage Ⅳ colorectal cancer. We will recruit at least 200 patients for this study.
- Trial name
- NCT00173472
- Testing
- Chemotherapy
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05902988
- Testing
- VLS-1488
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Volastra Therapeutics, Inc.
Localized Oesogastric Adenocarcimona, MSI and or dMMR
Pre-operative Nivolumab and Ipilimumab, Followed by Post-operative Nivolumab, for MSI/dMMR Oeso-gastric Adenocarcinoma.
This is a non-randomized study, open label phase II study. The purpose of this study is to evaluate the complete pathologic response rate (cPRR) with neoadjuvant nivolumab and ipilimumab combination in patients with MSI and/or…
- Trial name
- NEONIPIGA (NCT04006262)
- Testing
- Nivolumab 10 MG/ML, Ipilimumab 200 MG in 40 ML Injection
- Where
- 15 sites in France
- Volunteers
- 32 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Colorectal Cancer, Colorectal Carcinoma
Microsatellite Instability in Colorectal Cancers
In this study, we aimed to identify the different histopathological features of tumors with microsatellite instability (MSI) compared to microsatellite stable (MSS) in patients who underwent surgery for colorectal cancer.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Microsatellite Instability High, Microsatellite Instability Low
- Trial name
- MSI-CRC (NCT05162248)
- Testing
- Microsatellite instability analysis
- Where
- Turkey (Türkiye)
- Volunteers
- 231 people
- Sponsor
- Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey
High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer
A Study of Sovilnesib in Subjects With Ovarian Cancer
This is a phase 1b study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of sovilnesib at different dose levels to establish the optimal dose of sovilnesib in subjects with selected advanced…
- Conditions
- High Grade Serous Adenocarcinoma of Ovary, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Chromosomal Instability
- Trial name
- NCT06084416
- Testing
- Sovilnesib
- Where
- 11 sites in United States
- Volunteers
- 150 people
- Sponsor
- Volastra Therapeutics, Inc.
Colorectal Cancer, Microsatellite Instability
Aberrant Splicings Due to Microsatellite Instability in Colorectal Cancer : Physiopathological and Clinical Impact
MSI (Microsatellite Instability) colorectal cancer (CRC) show improved survival, are less prone to metastasis and show poor response to chemotherapy (compared to MSS tumors).
- Trial name
- NCT03447431
- Where
- France
- Volunteers
- 350 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Carcinoma, HIV Infections
Molecular Biology of Anal Cancer in HIV-Positive Patients
The molecular mechanisms involved in squamous cell carcinoma of the anus (SCCA) are poorly elucidated. HIV-positive and renal transplant patients are at high risk for developing SCCA, indicating that immune suppression plays a…
- Trial name
- NCT00952874
- Where
- Switzerland
- Volunteers
- 30 people
- Sponsor
- University Hospital, Geneva
Advanced Cancer, Anal Carcinoma
Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
In this study, participants with multiple types of advanced (unresectable and/or metastatic) solid tumors who have progressed on standard of care therapy will be treated with pembrolizumab (MK-3475).
- Conditions
- Advanced Cancer, Anal Carcinoma, Anal Cancer, Biliary Cancer
- Trial name
- NCT02628067
- Testing
- pembrolizumab
- Volunteers
- 1,609 people
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Cancer
Non-Invasive Diagnosis of Endometrial Cancer
The study aims to determine whether next generation sequencing and microsatellite analysis of cervical cytology is sensitive for the detection of endometrial carcinoma.
- Trial name
- NIECE (NCT05737797)
- Testing
- cervical cytology during surgery.
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Cytogenetic Abnormality, Radiation Exposure
Genomic Instability in Vascular Surgeons
The past two decades have witnessed the development and growth of the endovascular techniques, however, this new technology is not exempt from risks, since its use requires an ionizing radiation exposure to both patients and…
- Trial name
- IRADIENT (NCT04363190)
- Testing
- Cytogenetic analysis
- Where
- Spain
- Volunteers
- 28 people
- Sponsor
- Hospital Clínico Universitario de Valladolid
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Metastatic Cancer Colorectal
iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab
This is a non-randomized study, open label phase II study. The purpose of this study is to evaluate disease control rate (DCR) by RECIST and iRECIST at 12 weeks.
- Trial name
- NIPICOL (NCT03350126)
- Testing
- Ipilimumab 200 MG in 40 ML Injection, Nivolumab 10 MG/ML
- Where
- 8 sites in France
- Volunteers
- 57 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Gastric Cancer, Microsatellite Instability
TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.
INFINITY is a Phase II, multicentre, single-arm, multi-cohort trial aimed at evaluating the activity and safety of the combination of tremelimumab and durvalumab as neoadjuvant (Cohort 1) and definitive (Cohort 2) treatment for…
- Trial name
- INFINITY (NCT04817826)
- Testing
- Durvalumab, Tremelimumab
- Where
- Italy
- Volunteers
- 31 people
- Sponsor
- Gruppo Oncologico del Nord-Ovest
Genome Instability, Genetic Predisposition to Disease
Mutational Oncology in Clinical Practice
The study of biological profiling is of fundamental importance in the diagnosis and treatment of many diseases, particularly oncological ones, and for this reason, the integration of molecular characterization into clinical…
- Conditions
- Genome Instability, Genetic Predisposition to Disease, Gene Rearrangement
- Trial name
- FPG-500 (NCT06020625)
- Testing
- Diagnostic Test
- Where
- Italy
- Volunteers
- 20,000 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Bladder Cancer, Genomic Instability
Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy
This study will allow the investigators to better assess the efficiency of neoadjuvant chemotherapy before cystectomy by training a predictive model on different patient cohorts with bladder cancer.
- Trial name
- SELECT (NCT06294054)
- Testing
- neoadjuvant chemotherapy with cisplatine
- Where
- 7 sites in France
- Volunteers
- 707 people
- Sponsor
- University Hospital, Rouen
Carcinoma, Renal Cell, Head and Neck Neoplasm
Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types
This is a Phase 2, non-randomised, open-label, multicentric study to investigate the efficacy and safety of nivolumab monotherapy in 6 cohorts of patients with specific rare cancers who have unresectable locally advanced or…
- Conditions
- Carcinoma, Renal Cell, Head and Neck Neoplasm, Skin Neoplasms, Microsatellite Instability
- Trial name
- AcSé (NCT03012581)
- Testing
- Nivolumab
- Where
- France
- Volunteers
- 269 people
- Sponsor
- UNICANCER